Skip to main content
BMC Medical Co., Ltd. logo

BMC Medical Co., Ltd. — Investor Relations & Filings

Ticker · 301367 ISIN · CNE100005WQ4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 528 across all filing types
Latest filing 2026-04-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301367

About BMC Medical Co., Ltd.

https://www.bmc-medical.com

BMC Medical Co., Ltd. specializes in the development and distribution of diagnostic and therapeutic solutions for sleep-disordered breathing and chronic respiratory conditions. The company’s core product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel positive airway pressure (BPAP) systems, and high-flow oxygen therapy equipment. These are complemented by a range of patient interfaces, including nasal, pillow, and full-face masks. BMC integrates digital health capabilities through cloud-based management platforms, enabling remote data analysis and patient monitoring. By focusing on technical innovation and clinical efficacy, the company provides integrated respiratory care systems designed to improve patient compliance and therapeutic outcomes for conditions such as obstructive sleep apnea and chronic obstructive pulmonary disease.

Recent filings

Filing Released Lang Actions
关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's decision to use idle raised funds for cash management. It details the board meeting resolution, the amount and purpose of the cash management, risk controls, and compliance with regulatory rules. It does not contain financial statements or detailed financial results but is a disclosure about the use of funds approved by the board. The document length is 4386 characters, which is relatively short and consistent with an announcement rather than a full report. It is not an annual or interim report, audit report, or earnings release. It is not a regulatory filing or certification letter. The content fits best with a Capital/Financing Update (CAP) as it relates to the management and use of raised capital funds for cash management purposes.
2026-04-22 Chinese
2025年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2025年度董事会工作报告" which translates to "2025 Annual Board of Directors Work Report." It contains detailed information about the board's activities, meetings held, resolutions passed, and the execution of shareholder meeting decisions throughout the year 2025. It also includes financial performance summaries such as revenue and net profit figures for 2025, indicating a review of the company's operations and governance over the year. The content focuses on the board's work and governance rather than presenting full financial statements or audit opinions. This aligns with the category of Board/Management Information (MANG), which covers announcements related to the company's board activities and management reports. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or a brief summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). It is not an Annual Report (10-K) because it lacks comprehensive financial statements and detailed financial disclosures. Therefore, the best fit is MANG.
2026-04-22 Chinese
中国国际金融股份有限公司关于北京瑞迈特医疗科技股份有限公司2025年度募集资金存放、管理与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report on the use, management, and storage of funds raised by Beijing Ruimait Medical Technology Co., Ltd. for the fiscal year 2025. It includes specifics on fundraising amounts, fund allocation, cash management, investment projects, and compliance with regulatory requirements. The presence of audit references, detailed financial tables, and compliance with securities regulations indicates this is a specialized audit or verification report related to fundraising activities rather than a full annual report or earnings release. The document is not a simple announcement or certification but a comprehensive report on fundraising fund usage and management. This matches the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific financial activities, excluding full annual reports. FY 2025
2026-04-22 Chinese
2025年度独立董事述职报告（孙培睿）
Board/Management Information Classification · 95% confidence The document is titled '2025 年度独立董事述职报告' which translates to '2025 Independent Director's Work Report'. It is a detailed report by an independent director about their duties, attendance, opinions on company matters, communication with auditors, and protection of shareholder interests during the year 2025. The content focuses on the independent director's activities and responsibilities rather than financial results or audit opinions alone. It is not an annual report, audit report, or earnings release. It is a specialized report related to board/management information, specifically the independent director's report on their duties and observations. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2026-04-22 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled as a remuneration management system for directors and senior management of a company. It details the principles, structure, performance assessment, payment procedures, and clawback policies related to compensation for directors and senior executives. There is no indication that this is an announcement of a report, nor does it contain financial statements or earnings data. It is a detailed policy document about executive compensation, which fits the definition of Remuneration Information filings. Therefore, the document should be classified as DEF 14A (Remuneration Information). The document length is under 5,000 characters but contains substantive policy content, not just an announcement or certification, so it is not RPA or RNS.
2026-04-22 Chinese
北京国枫律师事务所关于北京瑞迈特医疗科技股份有限公司2025年限制性股票激励计划调整授予价格、作废部分已授予尚未归属的限制性股票及第一个归属期符合归属条件的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the grant price, cancellation of some unvested restricted stocks, and confirmation of the first vesting period conditions under the 2025 restricted stock incentive plan of Beijing Ruimait Medical Technology Co., Ltd. It references relevant laws, company board and shareholder meetings, and audit reports. The document is a legal opinion on stock incentive plan matters, not a financial report, earnings release, or management discussion. It is not a proxy solicitation or voting result announcement. It is a specialized legal opinion related to stock incentive adjustments and compliance with regulatory requirements. Therefore, it fits best under Regulatory Filings (RNS) as a legal compliance document that does not fit other specific categories.
2026-04-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.